NCT02591290View on ClinicalTrials.gov

Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 20, 2015

Primary Completion Date

March 16, 2016

Study Completion Date

March 16, 2016

Conditions
MeningitisMeningococcal MeningitisMeningococcal Infections
Interventions
BIOLOGICAL

Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate

0.5 mL, Intramuscular (2 doses with 8-week interval)

Trial Locations (1)

532-0003

Osaka

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02591290 - Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects | Biotech Hunter | Biotech Hunter